Immunoprecise Revenue

IPA
 Stock
  

USD 3.84  0.04  1.05%   

Immunoprecise Antibodies fundamentals help investors to digest information that contributes to Immunoprecise Antibodies' financial success or failures. It also enables traders to predict the movement of Immunoprecise Stock. The fundamental analysis module provides a way to measure Immunoprecise Antibodies' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Immunoprecise Antibodies stock. This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.
  
Refresh
Immunoprecise Antibodies Deferred Revenue is projected to increase significantly based on the last few years of reporting. The past year's Deferred Revenue was at 1.28 Million. The current year Cost of Revenue is expected to grow to about 7.3 M, whereas Revenues is forecasted to decline to about 19.1 M.

Immunoprecise Revenue Analysis

Immunoprecise Antibodies' Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.

Immunoprecise Antibodies Revenues

19.12 Million

Share
Revenue 
 = 
Money Received 
Discounts and Returns 
More About Revenue | All Equity Analysis

Current Immunoprecise Antibodies Revenue

    
  19 M  
Most of Immunoprecise Antibodies' fundamental indicators, such as Revenue, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Immunoprecise Antibodies is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

Immunoprecise Revenue Historical Pattern

Today, most investors in Immunoprecise Antibodies Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Immunoprecise Antibodies' growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's revenue growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Immunoprecise Antibodies revenue as a starting point in their analysis.
 Immunoprecise Antibodies Revenue 
Share
      Timeline 
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include product or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
Compare to competition

Immunoprecise Deferred Revenue

Deferred Revenue

1.31 Million

Share
Immunoprecise Antibodies Deferred Revenue is projected to increase significantly based on the last few years of reporting. The past year's Deferred Revenue was at 1.28 Million
Based on the latest financial disclosure, Immunoprecise Antibodies reported 19 M of revenue. This is 99.75% lower than that of the Healthcare sector and 97.44% lower than that of the Biotechnology industry. The revenue for all United States stocks is 99.8% higher than that of the company.
Immunoprecise Antibodies is considered the number one company in revenue category among related companies. Market size based on revenue of Biotechnology industry is currently estimated at about 35.35 Billion. Immunoprecise Antibodies adds roughly 19 Million in revenue claiming only tiny portion of stocks in Biotechnology industry.

Immunoprecise Antibodies Institutional Holders

Institutional Holdings refers to the ownership stake in Immunoprecise Antibodies that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Immunoprecise Antibodies' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Immunoprecise Antibodies' value.
Security TypeSharesValue
Ingalls Snyder LlcCommon Shares932.2 K4.8 M
Citadel Advisors LlcCall Options296.6 K1.5 M
Bank Of MontrealCommon Shares140.5 K718 K
Ikarian Capital LlcCommon Shares77.7 K399 K
Bank Of America CorpCommon Shares57.5 K295 K
Susquehanna International Group LlpPut Options36.1 K186 K
Gradient Capital Advisors LlcCommon Shares20 K103 K
Jpmorgan Chase CoCommon Shares19.9 K102 K
Geode Capital Management LlcCommon Shares17.5 K89 K

Immunoprecise Fundamentals

About Immunoprecise Antibodies Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Immunoprecise Antibodies's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Immunoprecise Antibodies using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Immunoprecise Antibodies based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Last ReportedProjected for 2022
Deferred Revenue1.3 M1.3 M
Cost of Revenue7.3 M7.3 M
Revenues20.6 M19.1 M
ImmunoPrecise Antibodies Ltd., together with its subsidiaries, engages in antibody production and related services in the United States, Canada, Europe, and internationally. ImmunoPrecise Antibodies Ltd. was incorporated in 1983 and is based in Victoria, Canada. Immunoprecise Antibodies operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 73 people.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Immunoprecise Antibodies without increasing your portfolio risk or giving up expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate.risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Competition Analyzer Now

   

Competition Analyzer

Analyze and compare many basic indicators for a group of related or unrelated entities
All  Next Launch Module

Becoming a Better Investor with Macroaxis

Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Immunoprecise Antibodies using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Please see Immunoprecise Antibodies Piotroski F Score and Immunoprecise Antibodies Altman Z Score analysis. Note that the Immunoprecise Antibodies information on this page should be used as a complementary analysis to other Immunoprecise Antibodies' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Efficient Frontier module to plot and analyze your portfolio and positions against risk-return landscape of the market..

Complementary Tools for Immunoprecise Stock analysis

When running Immunoprecise Antibodies price analysis, check to measure Immunoprecise Antibodies' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immunoprecise Antibodies is operating at the current time. Most of Immunoprecise Antibodies' value examination focuses on studying past and present price action to predict the probability of Immunoprecise Antibodies' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Immunoprecise Antibodies' price. Additionally, you may evaluate how the addition of Immunoprecise Antibodies to your portfolios can decrease your overall portfolio volatility.
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Go
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Go
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Go
My Watchlist Analysis
Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
Go
Price Transformation
Use Price Transformation models to analyze depth of different equity instruments across global markets
Go
Global Markets Map
Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
Go
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Go
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
Go
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
Go
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets
Go
Watchlist Optimization
Optimize watchlists to build efficient portfolio or rebalance existing positions based on mean-variance optimization algorithm
Go
Fundamental Analysis
View fundamental data based on most recent published financial statements
Go
Is Immunoprecise Antibodies' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Immunoprecise Antibodies. If investors know Immunoprecise will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Immunoprecise Antibodies listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
90.4 M
Quarterly Revenue Growth YOY
0.066
Return On Assets
-0.19
Return On Equity
-0.43
The market value of Immunoprecise Antibodies is measured differently than its book value, which is the value of Immunoprecise that is recorded on the company's balance sheet. Investors also form their own opinion of Immunoprecise Antibodies' value that differs from its market value or its book value, called intrinsic value, which is Immunoprecise Antibodies' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Immunoprecise Antibodies' market value can be influenced by many factors that don't directly affect Immunoprecise Antibodies' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Immunoprecise Antibodies' value and its price as these two are different measures arrived at by different means. Investors typically determine Immunoprecise Antibodies value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Immunoprecise Antibodies' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.